The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone. METHODS: We conducted a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab in patients with early-stage NSCLC. Participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned in a 1:1 ratio to receive neoadjuvant pembrolizumab (200 mg) or placebo once every 3 weeks, each of which was given with cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every 3 weeks for up to 13 cycles. The dual primary end points were event-free survival (the time from randomization to the first occurrence of local progression that precluded the planned surgery, unresectable tumor, progression or recurrence, or death) and overall survival. Secondary end points included major pathological response, pathological complete response, and safety. RESULTS: A total of 397 participants were assigned to the pembrolizumab group, and 400 to the placebo group. At the prespecified first interim analysis, the median follow-up was 25.2 months. Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group (hazard ratio for progression, recurrence, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.72; P<0.001). The estimated 24-month overall survival was 80.9% in the pembrolizumab group and 77.6% in the placebo group (P = 0.02, which did not meet the significance criterion). A major pathological response occurred in 30.2% of the participants in the pembrolizumab group and in 11.0% of those in the placebo group (difference, 19.2 percentage points; 95% CI, 13.9 to 24.7; P<0.0001; threshold, P = 0.0001), and a pathological complete response occurred in 18.1% and 4.0%, respectively (difference, 14.2 percentage points; 95% CI, 10.1 to 18.7; P<0.0001; threshold, P = 0.0001). Across all treatment phases, 44.9% of the participants in the pembrolizumab group and 37.3% of those in the placebo group had treatment-related adverse events of grade 3 or higher, including 1.0% and 0.8%, respectively, who had grade 5 events. CONCLUSIONS: Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery. Overall survival did not differ significantly between the groups in this analysis. (Funded by Merck Sharp and Dohme; KEYNOTE-671 ClinicalTrials.gov number, NCT03425643.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given the lack of successful trials in the perioperative space in HCC, no surrogate end point has been validated yet, as is the case for pCR in patients with NSCLC20,120 and breast cancer8.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [120]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ICI-treatment is approved for the treatment of NSCLC patients in the localized and metastatic setting regardless of PD-L1 status2–4, many patients still fail to achieve clinically meaningful responses.”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since results from one of the first clinical trials of such a therapeutic approach in patients with NSCLC were reported in 2018 (ref. 19), the efficacy and safety of neoadjuvant ICIs have been firmly established in multiple tumour types, with FDA approvals for two indications (NSCLC20,120 and triple-negative breast cancer8).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Self-citationOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationFelip, E., Altorki, N. K., Zhou, C., Csőszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A. V., Akopov, A. L., Martínez‐Martí, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,497
Self-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430
Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30453-8 · Cited by 841
Self-citationO'Brien, M. E. R., Paz-Ares, L. G., Marreaud, S. I., Dafni, U. G., Oselin, K., Havel, L., Esteban, E., Isla, D., Martínez‐Martí, A., Faehling, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00518-6 · Cited by 801
Self-citationHendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 685
On the Restricted Mean Survival Time Curve in Survival Analysis
Zhao, L., Claggett, B. L., Tian, L., Uno, H., Pfeffer, M. A., Solomon, S. D., Trippa, L., & Wei, L. (2015) · Biometrics · doi:10.1111/biom.12384 · Cited by 265
Chaft, J. E., Öezkan, F., Kris, M. G., Bunn, P. A., Wistuba, I. I., Kwiatkowski, D. J., Owen, D. H., Tang, Y., Johnson, B. E., Lee, J. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01962-5 · Cited by 255
Self-citationMultiple Testing in Group Sequential Trials Using Graphical Approaches
Maurer, W., & Bretz, F. (2013) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2013.807748 · Cited by 124
Lü, S., Wu, L., Zhang, W., Zhang, P., Wang, W., Fang, W., Xing, W., Chen, Q., Mei, J., Yang, L. T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.36_suppl.425126 · Cited by 94
Provencio-Pulla, M., Nadal, E., González-Larriba, J. L., Martínez‐Martí, A., Bernabé, R., Bosch‐Barrera, J., Casal, J., Calvo, V., Insa, A., Aix, S. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.8501 · Cited by 63
Flagged first, then by citations
Research works printed but not linked: 2
- Brierly JD Gospodarowicz MK Wittekind C. TNM classification of malignant tumors. 8th ed. New York: John Wiley 2016.
- Heymach JV Harpole D Mitsudomi T et al. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. In: Proceedings and Abstracts of the 114th Annual Meeting of the American Association for Cancer Research April 14–19 2023. Orlando FL: American Association for Cancer Research 2023. abstract.
Cited by
Sorted by citations
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Heymach, J. V., Harpole, D. H., Mitsudomi, T., Taube, J. M., Gálffy, G., Hochmair, M. J., Winder, T. L., Zukov, R. A., Garbaos, G., Gao, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304875 · Cited by 835
Self-citationHendriks, L. E. L., Remón, J., Finn, C. F., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 690
Perioperative Nivolumab in Resectable Lung Cancer
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lü, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311926 · Cited by 574
Self-citationNeoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Uppaluri, R., Haddad, R. I., Tao, Y., Tourneau, C. L., Lee, N. Y., Westra, W. H., Chernock, R. D., Tahara, M., Harrington, K. J., Klochikhin, A. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415434 · Cited by 473
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Lü, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Neotorch Investigators, Fang, W., Xing, W., Chen, Q., Yang, L., et al. (2024) · JAMA · doi:10.1001/jama.2023.24735 · Cited by 405
Self-citation
Metadata
- Authors
- Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G. L., Bylicki, O., Rodríguez-Abreu, D., Chaft, J. E., Novello, S., Yang, J., Keller, S. M., Samkari, A., & Spicer, J. D.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- From Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA (H.W.); Centre Hospitalier de l’Université de Montréal (M.L.) and McGill University Health Centre (J.D.S.) — both in Montreal; Kanagawa Cancer Center, Yokohama (T.K.), and National Cancer Center Hospital East, Kashiwa (M.T.) — both in Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (S.-H.L.); the National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (S.G.), and Beijing Cancer Hospital, Peking University (K.-N.C.) — both in Beijing; University Hospitals Leuven, Leuven, Belgium (C.D.); Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas (D.R.-A.) — both in Spain; Zentralklinik Bad Berka, Bad Berka, Germany (E.E.); Sanatorio Parque, Cordoba, Argentina (G.L.M.); Hôpital d’I...
- Memorial Sloan Kettering Cancer Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 491-503
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11074923
- OpenAlex
- W4379209546
- Cited by
- 1,180
- References
- 18
- Citations by year
- 2026: 324 · 2025: 388 · 2024: 368 · 2023: 100
- FWCI
- 216.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Acceda (Universidad de Las Palmas de Gran Canaria) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Merck Sharp and Dohme LLC, a subsidiary of Merck & Co, Inc
- National Cancer Institute (P30 CA008748)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- pembrolizumab, early-stage non-small cell lung cancer, perioperative immunotherapy, PD-1 inhibitors, cisplatin-based chemotherapy, event-free survival, overall survival, pathological response, pathological complete response, N2 disease, resectable lung cancer, treatment safety, immune-related adverse events
- MeSH terms
- Adjuvants, Immunologic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Combined Modality Therapy, Humans, Lung Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
